We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The Dow 30 has set a new record high during today’s Hump Day session, as the blue-chip index extends its winning streak to six straight days. Ultimately, it gained just 90 points, +0.25%, after ticking down in the final minutes of regular trading from session highs. Led by Walgreens (WBA - Free Report) and Nike (NKE - Free Report) , at +1.6% and +1.4%, respectively, its modestly higher performance outpaced the other indexes on the day.
The S&P 500 also dipped in the final minutes before the closing bell off its daily highs, but managed to notch a new all-time high close of its own — the third time in the past four trading days. The broader index gained +0.14% Wednesday, led by a +10% jump from biopharma major Biogen (BIIB - Free Report) on reports that the company — which developed some of the most successful drugs to treat multiple sclerosis (MS), including Avonex, Tysabri and Tecfidera — may be sold to Korean conglomerate Samsung for more than $40 billion. Biogen’s market cap had been around $35 billion.
The Nasdaq closed slightly in the red today, -0.10%, as the tech-heavy index finds its equilibrium. As we’ve noted here recently, this will have been the first year in the past five that the Nasdaq underperformed the S&P; in fact, the cooling down of the index follows terrific growth in the previous two years: +35% in 2019 and +44% in 2020. The small-cap Russell 2000 added +0.12% on the day, but still trails its larger-cap index brethren year to date.
This morning, we saw a record headline in advance U.S. trade in goods deficit: -$97.8 billion, accelerating 17.5% from previous levels on an import/export imbalance made possible by very high domestic demand while global economies beg off a bit. Industrial supplies were +10% on the import side but -2.3% on exports, with consumer goods imports +4.5% and exports -2.1%. The U.S. goods gap for the year is currently $984.6 billion, on pace for the biggest domestic shortfall on record.
But nothing essentially has changed today. Market participants are looking for their opportunities where they exist; however, value plays look to have dried up during the past few sessions that account for the front end of the Santa Claus Rally. Until we see an augmentation to the overall economic narrative going into 2022, we expect to continue on with muted bullish sentiment overall.
Image: Shutterstock
Dow, S&P Set Fresh All-Time Closing Highs
The Dow 30 has set a new record high during today’s Hump Day session, as the blue-chip index extends its winning streak to six straight days. Ultimately, it gained just 90 points, +0.25%, after ticking down in the final minutes of regular trading from session highs. Led by Walgreens (WBA - Free Report) and Nike (NKE - Free Report) , at +1.6% and +1.4%, respectively, its modestly higher performance outpaced the other indexes on the day.
The S&P 500 also dipped in the final minutes before the closing bell off its daily highs, but managed to notch a new all-time high close of its own — the third time in the past four trading days. The broader index gained +0.14% Wednesday, led by a +10% jump from biopharma major Biogen (BIIB - Free Report) on reports that the company — which developed some of the most successful drugs to treat multiple sclerosis (MS), including Avonex, Tysabri and Tecfidera — may be sold to Korean conglomerate Samsung for more than $40 billion. Biogen’s market cap had been around $35 billion.
The Nasdaq closed slightly in the red today, -0.10%, as the tech-heavy index finds its equilibrium. As we’ve noted here recently, this will have been the first year in the past five that the Nasdaq underperformed the S&P; in fact, the cooling down of the index follows terrific growth in the previous two years: +35% in 2019 and +44% in 2020. The small-cap Russell 2000 added +0.12% on the day, but still trails its larger-cap index brethren year to date.
This morning, we saw a record headline in advance U.S. trade in goods deficit: -$97.8 billion, accelerating 17.5% from previous levels on an import/export imbalance made possible by very high domestic demand while global economies beg off a bit. Industrial supplies were +10% on the import side but -2.3% on exports, with consumer goods imports +4.5% and exports -2.1%. The U.S. goods gap for the year is currently $984.6 billion, on pace for the biggest domestic shortfall on record.
But nothing essentially has changed today. Market participants are looking for their opportunities where they exist; however, value plays look to have dried up during the past few sessions that account for the front end of the Santa Claus Rally. Until we see an augmentation to the overall economic narrative going into 2022, we expect to continue on with muted bullish sentiment overall.
Questions or comments about this article and/or its author? Click here>>